| pubmed-article:16563806 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16563806 | lifeskim:mentions | umls-concept:C1519941 | lld:lifeskim |
| pubmed-article:16563806 | lifeskim:mentions | umls-concept:C1510438 | lld:lifeskim |
| pubmed-article:16563806 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16563806 | pubmed:dateCreated | 2006-9-4 | lld:pubmed |
| pubmed-article:16563806 | pubmed:abstractText | Regulatory and competitive pressure to reduce the QT interval prolongation risk of potential new drugs has led to focus on methods to test for inhibition of the human ether-a-go-go-related gene (hERG)-encoded K+ channel, the primary molecular target underlying this safety issue. Here we describe the validation of a method that combines medium-throughput with direct assessment of channel function. | lld:pubmed |
| pubmed-article:16563806 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16563806 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16563806 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16563806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16563806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16563806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16563806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16563806 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16563806 | pubmed:issn | 1056-8719 | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:SullivanMM | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:OrmeAA | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:SullivanEE | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:HeapyC GCG | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:JacobsonII | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:DingMM | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:PollardC ECE | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:HammondT GTG | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:HargreavesA... | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:DavisA MAM | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:AlbertsonNN | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:PerssonFF | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:EasterAA | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:Abi-GergesNN | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:HenthornD CDC | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:Bridgland-Tay... | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:SmallB GBG | lld:pubmed |
| pubmed-article:16563806 | pubmed:author | pubmed-author:ValentinJ-PJP | lld:pubmed |
| pubmed-article:16563806 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16563806 | pubmed:volume | 54 | lld:pubmed |
| pubmed-article:16563806 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16563806 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16563806 | pubmed:pagination | 189-99 | lld:pubmed |
| pubmed-article:16563806 | pubmed:dateRevised | 2008-10-28 | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:meshHeading | pubmed-meshheading:16563806... | lld:pubmed |
| pubmed-article:16563806 | pubmed:articleTitle | Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. | lld:pubmed |
| pubmed-article:16563806 | pubmed:affiliation | Safety Assessment UK, AstraZeneca R&D Alderley Park, Macclesfield, SK10 4TG, UK. | lld:pubmed |
| pubmed-article:16563806 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16563806 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16563806 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16563806 | lld:pubmed |
